Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and
clonal evolution. The molecular profile of CRC is routinely assessed in surgical or bioptic …

The mismatch repair (MMR) system which detects and corrects base mismatches and
insertions and deletions that occur during DNA synthesis is deregulated in approximately …

Molecular alterations in genes involved in DNA mismatch repair (MMR) promote cancer
initiation and foster tumour progression. Cancers deficient in MMR frequently show …

Entrectinib is a first-in-class pan-TRK kinase inhibitor currently undergoing clinical testing in
colorectal cancer and other tumor types. A patient with metastatic colorectal cancer …

Targeting HER2 is effective in 24% of ERBB2 amplified metastatic colorectal cancer;
however, secondary resistance occurs in most of the cases. We studied the evolution of …

Importance Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is
frequently due toRASandEGFRextracellular domain (ECD) mutations in metastatic …

Targeted therapies, chemotherapy, and immunotherapy are used to treat patients with
mismatch repair–deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer …

Purpose: Defects in the homologous recombination (HR) repair pathway are of clinical
interest due to sensitivity of HR-deficient cells to PARP inhibitors. We were interested in …

Inactivation of beta-2 microglobulin (B2M) is considered a determinant of resistance to
immune checkpoint inhibitors (ICPi) in melanoma and lung cancers. In contrast, B2M loss …

Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd),
often respond to immune checkpoint blockade therapies, while those with mismatch repair …